DelveInsight Releases Peptic Ulcer Pipeline Assessment Report
DelveInsight's "Peptic Ulcer - Pipeline Insight, 2026" report assesses the development of over 8 companies and 8 pipeline drugs for peptic ulcer treatments.
Research firm DelveInsight has published its "Peptic Ulcer - Pipeline Insight, 2026" report, providing an assessment of the current landscape for peptic ulcer treatments under development.
The report details the progress of more than eight companies and a similar number of pipeline drugs. It covers candidates in various stages, from preclinical research to clinical trials, offering insights into their profiles, therapeutic assessments by product type, stage, route of administration, and molecule type. The analysis also identifies inactive pipeline products.
Key findings include Fexuprazan, a potassium-competitive acid blocker (P-CAB) developed by Daewoong Pharmaceutical, which is in Phase III trials for peptic ulcers. Jiangsu Carephar Pharmaceuticals' KFP-H008, another P-CAB, is also in Phase III for duodenal ulcers. The report highlights over eight major companies engaged in developing therapies for peptic ulcers, with Daewoong Pharmaceutical's drug being in the most advanced stage.
The report provides a global overview and a detailed understanding of the disease and its treatment guidelines. It examines the mechanism of action, clinical studies, and development activities, including collaborations and licensing, for each drug candidate.